Apollo Endosurgery competitors

Results-focused senior executive whose strategic vision, leadership and commitment to success consistently led to dynamic gains in revenue, profit, operational performance and competitive advantage in US and global markets. Leverages instinctive ability to zero in on product and market potential to achieve objectives in start-up, turnaround and growth environments.Selected Achievements:Led $400 million division to record growth in worldwide sales and profit, with 14% year-over-year revenue gains and 10 point improvement in the bottom line.Key member of executive team that negotiated the $2.2 billion acquisition of Gyrus ACMI by Olympus Corporation.Built US division to $96.6 million in sales with average annual revenue growth of 35% for 3 consecutive years.Strategic forward thinker - initiated and spearheaded a comprehensive $700 million business restructuring to comply with changing healthcare laws and regulations while concurrently streamlining process, driving productivity and increasing customer satisfaction. The initiative resulted in a 15% reduction in expenses and a 5% revenue increase.

Dr. Singh was elected President and Chief Executive Officer of PerkinElmer effective December 30, 2019, and appointed to our board of directors in August 2019. Previously Dr. Singh was the President and Chief Operating Officer of the Company since January 2019. Dr. Singh joined PerkinElmer as the President of our Diagnostics business in May 2014. He was elected Senior Vice President in September 2016 and Executive Vice President in March 2018. Prior to joining PerkinElmer, Dr. Singh was General Manager of GE Healthcare’s Women’s Health business from 2012 to 2014, with responsibility for its mammography and bone densitometry businesses. Before that, Dr. Singh held senior executive level roles in strategy, business development and mergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in his career, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Middle East region. Dr. Singh holds a doctoral degree in chemistry from the University of Missouri-Columbia and a Master of Business Administration from Northeastern University. His research work has resulted in several issued patents and publications in peer reviewed journals. Dr. Singh has more than twenty-five years of leadership experience with global innovators in healthcare technology. He has spent the most recent six years developing unique insights into both our business and our opportunities for continued growth. Dr. Singh brings to our board a detailed understanding of the core technologies that we utilize and the operational strategies available to us as we continue to focus on innovating for a healthier world.

Geoff Martha is firmly establishing Medtronic as the undisputed global leader in healthcare technology. As chairman & CEO, Geoff leads the $30 billion company and its 90,000 employees in pursuit of fulfilling the Medtronic Mission to use technology to improve human welfare. He is recognized as a driven and innovative executive - ranking in Modern Healthcare’s 100 Most Influential People in Healthcare in 2020 and listed as the #1 CEO in healthcare technology by the Healthcare Technology Report in 2021.Geoff became CEO in April 2020. Under his leadership, Medtronic is putting the ‘tech’ in MedTech, leveraging the latest advances in cutting edge technology to transform healthcare. Fortune Magazine named Medtronic among the top 15 companies for its 2020 “Change the World” list, recognizing its swift efforts during the pandemic, and listed the company on its 2021 list of Most Admired Companies.Geoff joined Medtronic in 2011, and notably led the acquisition and integration of Covidien, the largest acquisition in the medical technology industry. Before joining Medtronic, Geoff spent 19 years at GE Healthcare and GE Capital.Geoff is a member of the Business Roundtable, and the World Economic Forum’s International Business Council. He also co-chairs the Taskforce on Health and Life Sciences for B20, a G20 engagement group.An ardent supporter of philanthropic and diversity initiatives, Geoff serves on the board of directors for the Medtronic Foundation, Children’s HeartLink, and the Northside Achievement Zone. He is part of OneTen, a coalition of cross-industry leaders committed to breaking down systemic barriers for Black Americans. He also serves as Medtronic’s Executive Sponsor to FIRST Robotics.Geoff received a bachelor’s degree in Finance from Pennsylvania State University, where he currently serves on the Development Council for its College of Liberal Arts. He was also captain of the Penn State men’s hockey team and later inducted into its Hockey Hall of Fame.

Founder of The Chopra Foundation, a non-profit entity for research on well-being and humanitarianism, and Chopra Global, a whole health company at the intersection of science and spirituality, is a world-renowned pioneer in integrative medicine and personal transformation. Chopra is a Clinical Professor of Family Medicine and Public Health at the University of California, San Diego and serves as a senior scientist with Gallup Organization.

David Andrew Fischel (born 1 April 1958) is a British businessman. He was formerly the chief executive of Intu Properties Group plc, a British shopping centre management and development company between 2001 and 2019.

Fareed Kureshy is a Chair Of The Board Of Directors / CTO at Therapeutic Holding Inc and is based in Phoenix, Arizona. He has worked as President at Behring Diagnostics, President at PB Diagnostics, and President & CEO at AUTOGENOMICS INC. Fareed attended SMU.

Mark Loguidice is a Manager at Spine Wave Inc and Chairman/CEO at Spine Wave Inc.

Scott Hirsch is a Chief Executive Officer at SOLTA MEDICAL INC and is based in New York City, New York. He has worked as Lead Equity Research Analyst, Specialty Pharmaceuticals and Global Generics at Credit Suisse Group AG and Vice President, Portfolio Manager at Plural Investments,LLC. Scott A. works or has worked as Portfolio Manager at Citadel. He studied at The Wharton School between 2004 and 2006 and Rhode Island School of Design.

Robert Reinhardt is a Chief Executive Officer at Defibtech.